Pharmacokinetics, Pharmacodynamics, and Safety of Moss-aGalactosidase A in Patients With Fabry Disease

NCT02995993 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

6

Enrollment

INDUSTRY

Sponsor class

Conditions

Fabry Disease

Interventions

DRUG: Moss-aGal (recombinant human alpha-galactosidase A produced in moss)

Sponsor

Greenovation Biotech GmbH

Collaborators

[object Object]